Granahan Investment Management Has Raised By $4.28 Million Its Bio Rad Labs (BIO) Position; Capitala Finance (CPTA) Sellers Increased By 2.69% Their Shorts

May 24, 2018 - By Maria Brooks

Bio-Rad Laboratories, Inc. (NYSE:BIO) Logo

Granahan Investment Management Inc increased Bio Rad Labs (BIO) stake by 55.64% reported in 2017Q4 SEC filing. Granahan Investment Management Inc acquired 18,000 shares as Bio Rad Labs (BIO)’s stock rose 2.21%. The Granahan Investment Management Inc holds 50,350 shares with $12.02 million value, up from 32,350 last quarter. Bio Rad Labs now has $8.55 billion valuation. The stock increased 0.30% or $0.859 during the last trading session, reaching $289.77. About 95,369 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 25.02% since May 24, 2017 and is uptrending. It has outperformed by 13.47% the S&P500.

Capitala Finance Corp (NASDAQ:CPTA) had an increase of 2.69% in short interest. CPTA’s SI was 126,200 shares in May as released by FINRA. Its up 2.69% from 122,900 shares previously. With 81,000 avg volume, 2 days are for Capitala Finance Corp (NASDAQ:CPTA)’s short sellers to cover CPTA’s short positions. The stock decreased 0.48% or $0.04 during the last trading session, reaching $8.26. About 103,206 shares traded or 29.52% up from the average. Capitala Finance Corp. (NASDAQ:CPTA) has declined 46.31% since May 24, 2017 and is downtrending. It has underperformed by 57.86% the S&P500.

More recent Bio-Rad Laboratories, Inc. (NYSE:BIO) news were published by: Globenewswire.com which released: “Research Report Identifies Bio-Rad Laboratories, Bright Horizons Family Solutions, Corbus Pharmaceuticals …” on May 18, 2018. Also Benzinga.com published the news titled: “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” on May 15, 2018. Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More” with publication date: May 17, 2018 was also an interesting one.

Investors sentiment increased to 1.13 in Q4 2017. Its up 0.35, from 0.78 in 2017Q3. It increased, as 23 investors sold BIO shares while 89 reduced holdings. 44 funds opened positions while 82 raised stakes. 18.57 million shares or 0.31% more from 18.51 million shares in 2017Q3 were reported. Oregon Employees Retirement Fund holds 0.03% or 7,474 shares. 200 are owned by Old Mutual Invsts (Uk). Captrust Fin Advsrs invested in 286 shares or 0% of the stock. Vanguard Group Inc holds 0.02% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 1.72 million shares. New York-based Quantbot Limited Partnership has invested 0.23% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Moreover, Raymond James & Assocs has 0% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 8,569 shares. Atlanta Capital Com L L C holds 1.85% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 1.47M shares. Hbk Limited Partnership owns 2,900 shares. Ameriprise Financial stated it has 0.01% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Tower Limited Liability Corporation (Trc) invested in 0.02% or 560 shares. Blackrock Inc invested 0.02% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Fort Washington Investment Oh accumulated 325,985 shares. Ahl Prns Llp accumulated 4,317 shares or 0.02% of the stock. Verition Fund Management Limited Co reported 0.09% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Trexquant Investment Lp stated it has 1,307 shares.

Granahan Investment Management Inc decreased Teradyne (NYSE:TER) stake by 17,881 shares to 68,428 valued at $2.87 million in 2017Q4. It also reduced Match Group stake by 316,646 shares and now owns 29,036 shares. Zendesk (NYSE:ZEN) was reduced too.

Among 5 analysts covering Bio-Rad Laboratories (NYSE:BIO), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Bio-Rad Laboratories had 20 analyst reports since August 7, 2015 according to SRatingsIntel. On Thursday, July 13 the stock rating was maintained by Jefferies with “Buy”. The rating was maintained by Jefferies with “Buy” on Thursday, June 8. On Wednesday, April 12 the stock rating was maintained by Jefferies with “Buy”. On Wednesday, September 27 the stock rating was maintained by Jefferies with “Buy”. Jefferies maintained the stock with “Buy” rating in Friday, April 28 report. Jefferies maintained Bio-Rad Laboratories, Inc. (NYSE:BIO) rating on Friday, October 20. Jefferies has “Buy” rating and $285.0 target. The firm has “Buy” rating by Wells Fargo given on Tuesday, March 20. The firm has “Outperform” rating by Wells Fargo given on Wednesday, February 28. The company was downgraded on Friday, February 16 by C.L. King. The firm earned “Buy” rating on Thursday, October 13 by CL King.

Since December 14, 2017, it had 0 insider purchases, and 1 insider sale for $1.24 million activity. TSINGOS CHRISTINE A sold $1.24 million worth of Bio-Rad Laboratories, Inc. (NYSE:BIO) on Thursday, December 14.

Investors sentiment increased to 1.43 in Q4 2017. Its up 0.48, from 0.95 in 2017Q3. It is positive, as 6 investors sold Capitala Finance Corp. shares while 8 reduced holdings. 9 funds opened positions while 11 raised stakes. 2.22 million shares or 12.04% less from 2.53 million shares in 2017Q3 were reported. Tower Capital Limited Liability Company (Trc), New York-based fund reported 250 shares. Bb&T Ltd, a Virginia-based fund reported 175,242 shares. Hudock Grp Inc Lc invested in 750 shares or 0% of the stock. Kemper owns 228,737 shares or 0.73% of their US portfolio. Millennium Mngmt Limited Liability Company holds 0% or 85,145 shares. Ares Ltd owns 206,455 shares. Ancora Ltd has 0.02% invested in Capitala Finance Corp. (NASDAQ:CPTA). Bancorporation Of America De holds 0% or 21,869 shares in its portfolio. Us Bank De invested in 500 shares. Baystate Wealth Management Ltd Liability Company holds 0% of its portfolio in Capitala Finance Corp. (NASDAQ:CPTA) for 1,000 shares. Susquehanna International Gp Llp reported 21,236 shares stake. Advsrs Asset reported 0.05% in Capitala Finance Corp. (NASDAQ:CPTA). Morgan Stanley stated it has 21,388 shares. Oppenheimer & Com holds 0.01% or 36,422 shares in its portfolio. Acadian Asset Mngmt Limited Liability Com accumulated 20,701 shares.

Among 11 analysts covering Capitala Finance (NASDAQ:CPTA), 4 have Buy rating, 0 Sell and 7 Hold. Therefore 36% are positive. Capitala Finance had 30 analyst reports since August 11, 2015 according to SRatingsIntel. JMP Securities downgraded the shares of CPTA in report on Friday, September 23 to “Market Perform” rating. The firm earned “Buy” rating on Tuesday, January 5 by Wunderlich. Deutsche Bank maintained the shares of CPTA in report on Friday, August 12 with “Buy” rating. The rating was maintained by Jefferies with “Buy” on Friday, November 3. Deutsche Bank maintained Capitala Finance Corp. (NASDAQ:CPTA) rating on Wednesday, August 12. Deutsche Bank has “Buy” rating and $18 target. The rating was downgraded by Wunderlich on Friday, September 23 to “Hold”. As per Wednesday, May 11, the company rating was downgraded by FBR Capital. The company was downgraded on Thursday, November 16 by Jefferies. On Thursday, March 10 the stock rating was maintained by Barclays Capital with “Overweight”. The rating was maintained by Keefe Bruyette & Woods on Sunday, October 22 with “Hold”.

More news for Capitala Finance Corp. (NASDAQ:CPTA) were recently published by: Pehub.com, which released: “Capitala Group opens Manhattan office, hires Stotler as director” on May 23, 2018. Prnewswire.com‘s article titled: “Faruqi & Faruqi, LLP is Investigating Capitala Finance Corp. (CPTA) on Behalf of its Shareholders” and published on May 03, 2018 is yet another important article.

Capitala Finance Corp. is a Business Development Company specializing in traditional mezzanine, senior subordinated and unitranche debt, first-lien and second-lien loans, equity investments in sponsored and non-sponsored lower and traditional middle market companies. The company has market cap of $132.01 million. The fund targets companies in the business services, commercial and professional services, manufacturing, consumer and retail, energy, and health-care industries. It has a 77.2 P/E ratio. It typically considers investments in the United States.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Maria Brooks

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: